Home Compare JNJ vs NOVN.SW
Stock Comparison · Industry comparison · Drug Manufacturers - General

Johnson & Johnson vs Novartis: Which Stock Looks Stronger in 2026?

Johnson & Johnson holds the cleaner structural position, with growth as the main driver and valuation adding further support. Novartis does not offset that deficit through any equally strong structural edge elsewhere. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Growth remains the main source of distance in the comparison. Johnson & Johnson leads by 18 points on the overall comparison score.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. JNJ and NOVN.SW share the same industry classification.

For a similarity-based comparison, see how Johnson & Johnson and Novartis each position within their functional peer groups in AssetNext.

Peer-Relative Score
JNJ
Johnson & Johnson
73
Peer-Score
Signal qualityHigh
vs
NOVN.SW
Novartis AG
55
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: JNJ vs NOVN.SW Profitability 69 60 Stability 86 78 Valuation 69 55 Growth 69 22 JNJ NOVN.SW
Gap Ranking
#1 Growth +47
#2 Valuation +14
#3 Profitability +9
#4 Stability +8
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for JNJ and NOVN.SW Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer JNJNOVN.SW Relative valuation Structural strength

Johnson & Johnson looks stronger on relative valuation, while the broader price setup remains mixed.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
Johnson & Johnson ranks near the top of the group on growth; Novartis AG sits in the weaker half.
Valuation
On valuation, the edge still sits with Johnson & Johnson, even though both profiles look solid.
Growth — Dominant Gap
JNJ
69
NOVN.SW
22
Gap+47in favour of JNJ

Earnings growth is one contributing factor within the growth lead.

What else supports the lead

Valuation still reinforces the same direction, which makes the lead look broader across the profile.

What this means for the comparison

Growth is the clearest driver, and valuation also supports Johnson & Johnson's broader structural position.

Explore full peer positioning in AssetNext

Break down the JNJ vs NOVN.SW comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-driven comparisons

Explore how JNJ and NOVN.SW each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.